Multi-Institutional Joint Research of Health-Related Quality of Life of Patients with Pruritus due to Chronic Liver Disease

Multi-Institutional Joint Research of Health-Related Quality of Life of Patients with Pruritus due to Chronic Liver Disease - HRQoL of Patients with Pruritus due to Chronic Liver Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022255

Enrollment

150

Registered

2016-05-09

Start date

2016-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease, Pruritus

Interventions

Nalfurafine Hydrochloride 2.5microgram 1cap per day The dose may be increased up to 5.0microgram per day depending on the symptom. Follow-up to 54 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with therapy-resistant pruritus due to chronic liver disease

Exclusion criteria

Exclusion criteria: Patients with a history of allergy to the ingredients in Nalfurafine Hydrochloride

Design outcomes

Primary

Measure	Time frame
SF-36 score before the therapy: once between -9w and -1W after the start of therapy: every outpatient visit between 0w and 9w once per 9 weeks between 10w and 54w	—

Secondary

Measure	Time frame
VAS scale	—

Countries

Japan

Contacts

Public ContactNobuaki Nakayama

Saitama Medical University Department of Gastroenterology and Hepatology

alfsg@saitama-med.ac.jp049-276-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026